Related Experiment Videos
[PVB therapy for advanced testicular cancer]
M Nakao1, S Nakagawa, K Toyoda
1Department of Urology, Kyoto Prefectural University of Medicine.
Hinyokika Kiyo. Acta Urologica Japonica
|November 1, 1989
Summary
Cisplatin-vinblastine-bleomycin (PVB) therapy demonstrated an 80% objective response rate in advanced testicular cancer patients. While effective, some cases with poor prognostic factors did not respond to PVB treatment.
Area of Science:
- Oncology
- Medical Oncology
- Urologic Oncology
Context:
- Advanced testicular cancer presents a significant clinical challenge.
- Chemotherapy regimens are crucial for managing metastatic disease.
- Evaluating treatment efficacy in diverse germ cell tumor subtypes is essential.
Purpose:
- To assess the efficacy of cisplatin-vinblastine-bleomycin (PVB) therapy in advanced testicular cancer.
- To determine the objective response rate and complete response in patients treated with PVB.
- To identify patient subgroups that may not benefit from PVB therapy.
Summary:
- Twelve patients with advanced testicular cancer (seminoma, teratocarcinoma, yolk sac tumor, embryonal carcinoma, mixed cell types) received PVB therapy.
- Ten patients had measurable metastatic lesions, achieving an 80% objective response rate, with three complete responses.
- Ten patients achieved no evidence of disease post-PVB and salvage surgery, though some with poor prognostic factors showed no response.
Impact:
- PVB therapy is a valuable treatment option for advanced testicular cancer.
- Understanding treatment response variations is critical for optimizing patient care.
- Further research may refine treatment strategies for patients with poor prognostic factors.